The following consensus is up to date for Dr. Martens as at 12 January 2024

  FY23A
Year ending
March 2023

(Reported)
FY24E
Year ending
March 2024
FY25E
Year ending
March 2025
FY26E
Year ending
March 2026
Revenue (£m) £1,000.3 £901.6 £938.9 £1,009.0
EBITDA (£m) £245.0 £205.2 £223.3 £245.8
PBT (£m) £159.4 £105.0 £117.2 £134.2
EPS 12.9p 8.0p 8.9p 10.2p
DPS 5.8p 4.6p 4.8p 5.0p

The above consensus is the mean average of forecasts gathered from 9 out of 9 covering sell-side analysts

Legal disclaimer

These financial forecasts are not prepared nor endorsed by Dr. Martens in any way. Dr. Martens has no current or pending duty to verify any individual estimates and assumes no responsibility to update, revise or otherwise comment on any of the information contained in these forecasts. It should be noted that financial forecasts are, by definition, forward looking, and are therefore subject to various risks and uncertainties which are subject to change at any time.